Mark C. McKenna

Filings by Mark C. McKenna span 6 companies, the busiest being Prometheus Biosciences, Inc., Bausch Health Companies Inc. and Apogee Therapeutics, Inc. Over a trading history stretching from 8 January 2019 to 3 September 2026, the count stands at 32 filings.

On the open market, the record shows 2 purchases worth €943k and 8 sales worth €14.2M. The net balance comes to €13.2M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 8 share grants and 11 option exercises.

The latest filing, published on 3 September 2026, reports a transaction in Apogee Therapeutics, Inc. The most recent open-market purchase was published on 16 December 2024, 676 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.